GET DAILY SIGNALSVoyager Therapeutics (VYGR): Analyst Targets Suggest +767% Potential Upside
Key Takeaways
- The central target of $15 is the arithmetic mean of seven verifiable analyst price targets on VYGR, rounded from a calculated mean of roughly $15.14.
- With the stock recently near $1.73, reaching $15 would require a rise of about 767% — a very large move by any standard.
- The seven targets used span a wide range from $8 to $25, with ratings clustered at Buy and Outperform.
- Bullish support rests on Voyager's TRACER capsid platform, partnership economics, and near-term clinical catalysts, including tau-PET data for its Alzheimer's candidate.
- The biggest risks are clinical failure, declining collaboration revenue, and a share price that has already fallen sharply and is trading near its 52-week low.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies applied across the market.
Breaking Down the Analyst Targets
Voyager Therapeutics, Inc. (VYGR) is a clinical-stage biotechnology company that develops gene-based therapies for neurological diseases using its TRACER adeno-associated virus (AAV) capsid discovery platform. Seven attributable analyst targets were reviewed for this analysis, spanning roughly $8 to $25 and carrying an arithmetic mean of about $15.14, rounded to $15. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The individual targets include H.C. Wainwright at $25 (September 2026), Guggenheim at $22 (June 2026), Oppenheimer at $18 (May 2026), Canaccord Genuity at $12 (October 2026), Citi at $11 (March 2026, reaffirmed in June), Wells Fargo at $10 (October 2026), and Wedbush at $8 (August 2026). Ratings are uniformly bullish, with Buy, Outperform, and Overweight designations and no current Sell ratings among these firms.
The wide $8-to-$25 dispersion reflects genuine disagreement about how to value a pre-commercial platform whose economics depend heavily on partner milestones and early-stage clinical readouts. Analysts on the high end emphasize the optionality of Voyager's wholly owned pipeline, while those near the low end weight the long, uncertain path to commercialization and reliance on collaboration revenue. This mean is a calculated average of individual targets, not an officially published consensus figure, and should not be read as a guarantee.
Current Market Position and Path Toward the Target
The stock recently traded around $1.73, with a market capitalization of roughly $107 million. Reaching the $15 central target would require an increase of approximately 767% from that level — a very large move. Voyager is also trading essentially at the bottom of its 52-week range of roughly $1.71 to $5.48, after a decline of more than 60% over the trailing year.
The path toward the target is therefore not one of incremental multiple expansion but of re-rating driven by clinical data. Voyager's revenue is expected to contract in the near term, from about $40 million in 2025 toward roughly $20 million in 2026, while the company remains unprofitable with negative earnings per share (EPS). A move toward $15 would depend almost entirely on successful trial results and renewed investor confidence in the pipeline rather than current fundamentals.
What Could Support a Move Toward the Target
The central bull case rests on Voyager's TRACER platform, which is designed to deliver genetic medicines across the blood-brain barrier — a capability validated by collaborations with partners such as Novartis and Neurocrine. Analysts note that milestone payments from these partnerships provide a revenue foundation and partially de-risk the platform.
The most significant near-term catalyst is tau-PET data for VY7523, an anti-tau monoclonal antibody for early Alzheimer's disease, which management has guided for the second half of 2026, with Citi pointing to the fourth quarter as the likely window. Additional wholly owned programs, including the VY-TAU01 and VY1706 tau candidates and the VY-SOD101 program for ALS (amyotrophic lateral sclerosis), broaden the pipeline. A strong balance sheet, with cash estimated to fund operations into 2027, reduces near-term financing risk and supports the argument that Voyager can advance its programs without immediate dilution.
What Could Prevent the Target From Being Reached
The principal risk is clinical. Neurological gene therapy and Alzheimer's programs carry high failure rates, and a disappointing readout for VY7523 or a safety event in any trial could compress valuation sharply. Voyager also remains heavily dependent on partner-led programs; if a collaborator deprioritizes a Voyager capsid, the perceived value of the platform could decline.
Financially, collaboration revenue is shrinking, and the company is not expected to be profitable in the near term. The share price has already fallen to a 52-week low, which can indicate both diminished investor confidence and technical weakness. As a small, unprofitable biotech, Voyager is also sensitive to sector-wide rotation and risk appetite, which can move the stock independently of its fundamentals.
Technical Levels and Market Structure
Voyager is trading near major support around $1.71, its 52-week low. Holding above that level is an important structural signal, while a break below it would open the downside with little recent history to act as a floor. On the upside, the $2 round-number level and the prior 52-week high near $5.48 represent the first meaningful resistance zones, well below the $15 target. The enormous distance between the current price and the analyst-derived target means conventional technical milestones do not yet map cleanly to the $15 objective.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ, and this horizon was not uniformly disclosed across the seven targets reviewed. Investors should monitor the tau-PET data for VY7523, expected in the second half of 2026, along with any updates on VY-TAU01, VY1706, and VY-SOD101. Quarterly earnings and revenue updates, changes in collaboration agreements, analyst target revisions, and the company's cash runway disclosures are also directly relevant to the target. Because Voyager remains data-driven, clinical catalysts will matter more than typical quarterly financial results.
Final Assessment
The $15 central target is a calculated average of seven analyst price targets ranging from $8 to $25, and it sits roughly 767% above the recent price near $1.73 — a very large required move. The bullish case is anchored in the TRACER platform, partner validation, a cash runway into 2027, and near-term Alzheimer's data, while the bear case points to clinical risk, declining collaboration revenue, and a stock already at its 52-week low. The wide dispersion among targets reflects genuine uncertainty about an early-stage pipeline. Whether Voyager approaches $15 depends primarily on successful clinical readouts and a re-rating of the platform, and no outcome is guaranteed.
Using AI Daily Buy/Sell Signals in Practice
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like VYGR, such tools can help traders track shifting momentum and spot emerging trends more efficiently than manual review. Traders can use the signals to discover opportunities, monitor existing positions, and identify changing patterns across the market. Explore the AI Daily Buy/Sell Signals to see how AI-driven analysis can support your own research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VYGR's RSI Oscillator is remaining in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +15.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 229 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.691) is normal, around the industry mean (2.974). P/E Ratio (-0.956) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of gene therapies for fatal and debilitating diseases of the central nervous system
Industry Biotechnology
Advertisement